Rebecca A. Guzman focuses on the representation of start-up and emerging growth companies with a focus on life science companies in the biotechnology, pharmaceutical, medical device, diagnostics and healthcare IT industries. Her practice spans the entire corporate lifecycle, from formation through liquidity. In addition to her company client counsel, Rebecca represents a number of prominent venture capital funds and institutional investors in their financing activities.
Rebecca is broadly experienced in M&A and currently serves as a vice chair of the M&A Division of the firm. She also has extensive experience and regularly advises in all areas of Delaware corporate and alternative entity law.
Rebecca is a graduate of the University of California, Berkeley, School of Law, where she won the Prosser Prize in Negotiations, and a graduate, with highest honors, of Lehigh University, where she was elected to Phi Beta Kappa. Before law school, Rebecca was a Fulbright Scholar in Jakarta, Indonesia.
Areas of Practice
- Venture Capital
- Life Sciences
Mergers and Acquisitions
- Delaware Corporate and Alternative Entity Law
Represented MissionOG, a Philadelphia-based venture capital firm focused on Fintech in a number of investments.
Represented Agent Capital, a healthcare venture capital firm in a number of investments.
Represented Venatorx Pharmaceuticals, Inc., a biopharmaceutical company developing next-generation antibiotics in a Series C Preferred Stock financing.
Represented 5Metis, Inc., a agrichemical company in its initial corporate structuring and Series A Preferred Stock financing.
Represented Early Bird Medical Inc., a medical device startup in its Series A Preferred Stock financing.
Represented Gliknik Inc., a privately held biopharmaceutical company, in its Series C Preferred Stock financing.
Represented Rellevate, Inc., a digital fintech company, in a Series Seed Preferred Stock financing.
Represented Shifa Biomedical, a drug discovery company, in its initial corporate structuring and capitalization.
Represented SIRPant Immunotherapeutics, a biotechnology company focused on the development of novel autologous cell therapy for solid tumors, in a $25 million Series A Preferred Stock financing, with BIOS Equity Partners III, LP as the lead investor.
Represented NephroDI, a pharmaceutical company focusing on concentration disorders of the kidney, in its initial corporate structuring and capitalization.
Represented Integral Molecular, a biotechnology company specializing in discovering therapeutic antibodies–and the industry leader in membrane protein solutions–in its research collaboration and licensing agreement with Context Therapeutics, a clinical-stage women’s oncology company, to advance a potential gynecological cancer therapy involving an anti-claudin 6 (CLDN6) bispecific monoclonal antibody.
Represented Patheon N.V. in connection with its $7.2 billion sale to Thermo Fisher Scientific, Inc.
Represented DowDuPont in a variety of matters, including in connection with the separation of its materials science, agriculture and specialty product businesses.
Represented Amulet Capital Partners in its sale of Synteract to Syneos Health.
Represented W.L. Ross in its sale, on behalf of funds managed by W.L. Ross, of its equity interests in Navigator Holdings Ltd.
Represented Alexander & Baldwin on its conversion to a REIT, including an internal realignment involving the serialization of its operating company and other subsidiaries.
Represented The Washington Companies in various matters, including the sale of their Modern Machinery Far East Russian business.
Represented JLL Partners and Water Street Healthcare Partners in the acquisition by their portfolio company MedPlast of Vention Medical.
Represented JLL Partners in its sale of Loar Group.
Represented Hg in its acquisition of a majority interest in the Rhapsody business of Orion Health Group Limited.
Represented ABRY Partners in various acquisitions, including in connection with its $1.325 billion sale of its majority interest in York Risk Services Group.
Represented Greenbriar Equity Group in connection with its acquisition of Lazer Spot.
Represented 3G Capital Partners and Burger King Worldwide in connection with its $11.5 billion merger transaction with Tim Hortons, Inc. and its issuance of $2.25 billion of second lien senior secured notes.
Represented Builders FirstSource, Inc. in connection with the financing of its acquisition of ProBuild.
Represented Investor Group in connection with its minority investment in a manufacturer of cabinetry.
- New York
- University of California, Berkeley, School of Law, J.D.
- Articles Editor and Senior Editor, Berkeley Journal of International Law
- won the Prosser Prize in Negotiations
- Lehigh University, B.A., with highest honors
- Phi Beta Kappa
- Duane Morris LLP
- Partner, 2022-present
- Associate, 2021
- Skadden, Arps, Slate, Meagher and Flom LLP
- Associate, 2016-2021
- Kirkland and Ellis LLP
- Associate, 2013-2016
Honors and Awards
- Named to Best Lawyers "Ones to Watch," 2023
- Named to the Philadelphia Business Journal's "Best of the Bar" for Corporate, 2022
- Board Member, Delaware Bar Foundation
Selected Speaking Engagements
- Presenter, “Review of Recent Delaware Decisions," Mergers & Acquisitions Pennsylvania Bar Institute CLE, April 8, 2022
- Moderator, “How Enterprise America is Re-tooling its Approach to Innovation," PACT Capital Conference, November 4, 2021